TY - JOUR
T1 - The SAMe-TT2R2 score and decision-making between a Vitamin K Antagonist or a Non-Vitamin K Antagonist Oral Anticoagulant in patients with atrial fibrillation
AU - Esteve-Pastor, María Asunción
AU - Roldán, Vanessa
AU - Valdés, Mariano
AU - Lip, Gregory Y H
AU - Marín, Francisco
PY - 2016
Y1 - 2016
N2 - Oral anticoagulation therapy is essential in patients with atrial fibrillation and clinicians need guidance on decision-making between the vitamin K antagonists (VKA), e.g. warfarin, or non-vitamin K antagonist oral anticoagulants. Observational studies have shown that patients who receive VKA therapy spend a significant percentage of their time with INR values outside of the therapeutic range (time in therapeutic range, TTR <60%.) Recently, a clinical score has been developed with commonly-encountered clinical features, the SAMe-TT2R2 score, to help decision-making with regards to whether a patient is likely to do well, or not, with a VKA. Those with a SAMe-TT2R2 score 0-1 are likely to do well on a VKA, whilst those with a SAMe-TT2R2 score ≥2 are on probability going to achieve suboptimal TTR. In this article, we provide an overview of the main published retrospective and prospective studies that have validated the SAMe-TT2R2 score and its value for decision-making in daily clinical practice.
AB - Oral anticoagulation therapy is essential in patients with atrial fibrillation and clinicians need guidance on decision-making between the vitamin K antagonists (VKA), e.g. warfarin, or non-vitamin K antagonist oral anticoagulants. Observational studies have shown that patients who receive VKA therapy spend a significant percentage of their time with INR values outside of the therapeutic range (time in therapeutic range, TTR <60%.) Recently, a clinical score has been developed with commonly-encountered clinical features, the SAMe-TT2R2 score, to help decision-making with regards to whether a patient is likely to do well, or not, with a VKA. Those with a SAMe-TT2R2 score 0-1 are likely to do well on a VKA, whilst those with a SAMe-TT2R2 score ≥2 are on probability going to achieve suboptimal TTR. In this article, we provide an overview of the main published retrospective and prospective studies that have validated the SAMe-TT2R2 score and its value for decision-making in daily clinical practice.
U2 - 10.1586/14779072.2016.1116941
DO - 10.1586/14779072.2016.1116941
M3 - Review article
C2 - 26559964
SN - 1477-9072
VL - 14
SP - 177
EP - 187
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
IS - 2
ER -